CKD
- ADVANCE: Intensive glycemic control (≤180) reduces risk of nephropathy
- CHOIR: Treating to a lower Hgb target with EPO reduced MI/Death/CHF/Stroke in Anemia with CKD; no conferred survival with target >13
- RENAAL: In T2DM and Nephropathy, Losartan 50-100 reduced ESRD risk
- IDEAL: Early vs. Late Dialysis in CKD; No survival difference